» Articles » PMID: 16288298

Normal Huntingtin Function: an Alternative Approach to Huntington's Disease

Overview
Specialty Neurology
Date 2005 Nov 17
PMID 16288298
Citations 273
Authors
Affiliations
Soon will be listed here.
Abstract

Several neurological diseases are characterized by the altered activity of one or a few ubiquitously expressed cell proteins, but it is not known how these normal proteins turn into harmful executors of selective neuronal cell death. We selected huntingtin in Huntington's disease to explore this question because the dominant inheritance pattern of the disease seems to exclude the possibility that the wild-type protein has a role in the natural history of this condition. However, even in this extreme case, there is considerable evidence that normal huntingtin is important for neuronal function and that the activity of some of its downstream effectors, such as brain-derived neurotrophic factor, is reduced in Huntington's disease.

Citing Articles

The Role of Brain-Derived Neurotrophic Factor as an Essential Mediator in Neuronal Functions and the Therapeutic Potential of Its Mimetics for Neuroprotection in Neurologic and Psychiatric Disorders.

Numakawa T, Kajihara R Molecules. 2025; 30(4).

PMID: 40005159 PMC: 11857940. DOI: 10.3390/molecules30040848.


Exploring the Connection Between Nanomaterials and Neurodegenerative Disorders.

Nanda S, Yi D Micromachines (Basel). 2024; 15(11).

PMID: 39597194 PMC: 11596582. DOI: 10.3390/mi15111382.


Neuroprotective Potential of Eugenol in Polyglutamine-Mediated Neurodegenerative Disease Using Transgenic Model.

Chongtham A, Agrawal N Dose Response. 2024; 22(4):15593258241291652.

PMID: 39410958 PMC: 11475233. DOI: 10.1177/15593258241291652.


Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.

Wu Y, Ma B, Liu C, Li D, Sui G Int J Mol Sci. 2024; 25(18).

PMID: 39337671 PMC: 11432175. DOI: 10.3390/ijms251810187.


Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies.

Kim L, Kundu B, Moretti P, Lozano A, Rahimpour S Neurotherapeutics. 2024; 21(6):e00452.

PMID: 39304438 PMC: 11585891. DOI: 10.1016/j.neurot.2024.e00452.